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Abstract
Aim: To psychometrically validate the Spanish version of the self-administered 2-item GAD-2 scale for screening
probable patients with generalised anxiety disorder (GAD).
Methods: The GAD-2 was self-administered by patients diagnosed with GAD according to DSM-IV criteria and by
age- and sex-matched controls who were recruited at random in mental health and primary care centres. Criteria
validity was explored using ROC curve analysis, and sensitivity, specificity and positive and negative predictive
values were determined for different cut-off values. Concurrent validity was also established using the HAM-A,
HADS, and WHODAS II scales.
Results: The study sample consisted of 212 subjects (106 patients with GAD) with a mean age of 50.38 years
(SD = 16.76). No items of the scale were left blank. Floor and ceiling effects were negligible. No patients with GAD
had to be assisted to complete the questionnaire. Reliability (internal consistency) was high; Cronbach’s α= 0.875. A
cut-off point of 3 showed adequate sensitivity (91.5%) and specificity (85.8%), with a statistically significant area
under the curve (AUC= 0.937, p < 0.001), to distinguish GAD patients from controls. Concurrent validity was also
high and significant with HAM-A (0.806, p < 0.001), HADS (anxiety domain, 0.825, p < 0.001) and WHO-DAS II (0.642,
p < 0.001) scales.
Conclusion: The Spanish version of the GAD-2 scale has been shown to have appropriate psychometric properties
to rapidly detect probable cases of GAD in the Spanish cultural context under routine clinical practice conditions.
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Background
Anxiety disorders are among the most common mental
disorders with a prevalence of 12% in the adult popula-
tion [1]. In the ESEMeD [2] epidemiologic study on
mental disorders conducted in six European countries,
past-year prevalence was 6% while life time prevalence
was 13.6%, with 1.9% prevalence in Spain (2.6% in
women and 1.2% in men). Generalised anxiety disorder
(GAD) studies in the general population in the United
States and Canada have found prevalences in the range
of 5-7%. These figures rise in the population visiting pri-
mary care health centres, with 19.5% of patients present-
ing some form of the most common anxiety disorders
(GAD, panic disorder, social anxiety disorder or post-
traumatic stress) [3]. Approximately 8% of those patients
are diagnosed with GAD, making it the most prevalent
anxiety disorder [4]. In a World Health Organisation
study applying ICD-10 criteria to more than 25,000 pri-
mary care patients in 14 countries, GAD prevalence was
7.9%, matching the values found in the Spanish primary
care population [5-7].
It is clear that GAD is under-diagnosed and only a mi-
nority of cases are detected in primary care services [8],
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possibly due to the fact that the use of diagnostic ques-
tionnaires constitutes a burden on routine practice, be-
cause of the impact on consultation time and the
associated cost [9]. There is therefore a need for simple
questionnaires that can be administered quickly in rou-
tine practice and also on Web health portals and for
Internet-based studies. The core symptom of GAD is
chronic, excessive and uncontrolled worry [10]. Both the
DSM-IV and ICD-10 classification systems [11,12] distin-
guish GAD from other anxiety and depressive disorders
[13]. However as is the case with other anxiety disorders,
GAD is frequently associated with other psychiatric dis-
eases: 80-90% of individuals meeting GAD criteria
present one or more other psychiatric disorders during
their lifetime [14]. The effects of GAD on health-related
quality of life (HRQL) are even greater than those
observed in major depression disorder, which is known
to be disabling and costly [15], and it is not possible to
totally explain these effects by comorbid diseases.
Several scales for assessing the presence of clinical
anxiety have been validated in our culture and are used
routinely. These include the Hamilton Anxiety Scale
(HAM-A) [16], Hospital Anxiety and Depression Scale
(HADS) [17], Covi Anxiety Scale [18], Clinical Anxiety
Scale (CAS) [19], State-Trait Anxiety Inventory (STAI)
[20], Generalized Anxiety Disorder Questionnaire-IV
(GAD-Q-IV) [21], and World Health Organization
Composite International Diagnostic Interview Short-
Form (CIDI-SF) [22], among others. Regardless of
whether they are patient self-administered or structured
interviews administered by the clinician, they all assess
the presence of anxiety symptoms and their severity, but
are not adequate for early detection or screening of
probable GAD cases and cannot be self-administered by
the patient without clinician supervision. Recently the
GAD-7 scale has been developed and validated [23,24].
It is an easy to use 7-item instrument, based on DSM-IV
criteria, for identifying probable GAD cases. It has excel-
lent psychometric properties, is easy to administer and
does not involve any burden for the patient or for the
clinician. Furthermore its shortness allows it to be used
in epidemiologic studies and also in remote health sur-
veys along with other health questionnaires. However it
has been suggested that the questionnaire be further
shortened to use only the first two items related to the
two main GAD symptoms, whence the GAD-2 scale [3].
The GAD-2 questionnaire has been proven to retain the
good psychometric properties of the extended version
and to have similar discriminant capability [3,25]. Given
the importance of early detection of anxiety disorders,
the GAD-2 has been proposed as a common first step
for screening GAD [3].
The aim of the present research was to develop a new
version of the GAD-2 questionnaire, culturally adapted
into Spanish for Spain and to assess its psychometric
properties for screening probable subjects with GAD in
daily medical practice.
Material and methods
The development of the GAD-2 cultural adaptation was
approached as an extension of the broader adaptation of
the GAD-7 scale, since items are shared with the latter.
The methodology used was the one currently recom-
mended for adapting psychometric instruments [26,27]
along with assumptions of classical test theory [28]. The
GAD-7 adaptation process started with a double transla-
tion from English followed by back-translation of the
adapted instrument. The process of the questionnaire
cultural adaptation was initiated with the duplicate
translation of the English original into Spanish by two
English-speaking native translators separately. Both
translations were reviewed by an Expert Panel including
4 clinicians (one of them a psychiatrist), 1 expert in clin-
ical research and 2 methodologists specialized in meas-
urement tasks. Then, both translations were merged into
a single reconciled version resolving discrepancies by full
agreement, which underwent a content validity process
by inter-rater agreement estimation. For that purpose, a
panel of 8 specialists in psychiatric disorders was
selected. These specialists independently assessed
whether each item did or did not properly measure
GAD (objective concept) and whether it could or could
not measure depression (distractor concept). The item-
objective congruence index was computed from the spe-
cialists’ ratings [29]. This index reaches the value of 1 in
case of perfect congruence in assigning the item to one
domain, and −1 when such congruence is lacking. The
conciliated version was administered to the pilot sample
together with a brief additional questionnaire to ascer-
tain the help needed to complete the questionnaire, the
difficulties encountered and socio-demographic vari-
ables. In view of the results obtained in the pilot test,
the questionnaire header was modified to emphasize the
frequency of symptom onset; the anchors of the re-
sponse categories were also modified. The final version
was translated back into English by two independent
translators separately and forwarded to the original
authors for conceptual equivalence assessment. The
structural validity was assessed through confirmatory
factor analysis, concurrent validity through the relation
with the HAM-A and HADS scales, and construct valid-
ity through the relation with the WHODAS II scale [30].
The entire process has been reported elsewhere [24].
Subsequently a second measurement study was per-
formed, administering the GAD-7 in conjunction with
the GAD-2 in order to determine whether there might
be differences between the extended and the abbreviated
versions. If differences do exist, we would like to be able
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to recommend that researchers use the scale version
more suited to their research needs, based on accuracy
and length. Furthermore it would not be advisable to use
the information gathered in previous studies using the
GAD-7 to deduce outcomes that would have been
obtained had the GAD-2 been used as a screening tool.
Study design
The present study was designed as a multicentre, obser-
vational, cross-sectional study conducted under routine
clinical practice conditions in primary care clinics, in
subjects diagnosed with GAD according to DSM-IV cri-
teria. Participating clinicians were family physicians
trained in applying DSM criteria and in the use of in-
strument measuring mental health (for example, Hamil-
ton scales) with more of 5 years of experience in visiting
outpatients at primary care settings. Standard diagnosis
of GAD was based in the Mini International Neuro-
psychiatric Interview. All subjects in the study – both
patients and controls – had to give their informed con-
sent in order to be enrolled in the study and have their
data analysed. The study protocol was approved by the
Research Ethics Committee of the Universidad Autón-
oma de Madrid and by the Research Committee of the
Spanish Society of Rural and General Medicine (SEMER-
GEN). At the time of recruitment, the GAD-7 question-
naire was administered to the sample of patients and
controls along with two other instruments: the Spanish
versions of the HAM-A [19] and the WHODAS II
(WHO 2000) [30]. Socio-demographic and medical rec-
ord data were also recorded at this visit.
In a second stage the concordance between the GAD-2
and GAD-7 was gauged in order to determine whether
the GAD-2 could have been used as a diagnostic tool in
studies were the GAD-7 had been used. The GAD-2 was
administered to a new sample composed of 60 patients.
This stage was also needed to assess the psychometric
capabilities of the GAD-2 alone. The sample was ran-
domly divided in two parts. In one part the GAD-2 was
presented before the GAD-7 and in the second part the
presentation order was reversed. Using this design it
would be possible to control for a trailing effect due to
presentation order.
Sample of patients
Patients were randomly screened in primary care set-
tings in urban areas of Madrid, Zaragoza and Barcelona
during office visits with study investigators. Once
screened, patient fulfilment of the following inclusion
criteria was checked: patients of either sex; over 18 years
of age; able to speak and understand Spanish; with a
known diagnosis of GAD (for the patient group, a diag-
nosis according to DSM-IV criteria under usual medical
practice conditions was required), either receiving no
anxiolytic treatment of any type or receiving anxiolytic
therapy but with anxiety symptoms still present (score ≥
16 points on the HAM-A). Likewise the following exclu-
sion criteria were verified: patients or subjects who, in
the investigator’s judgment, were in a state of health that
would not allow self-administered completion of self-
perceived health scales; were unable to understand or
answer the questions on the scale due to their educa-
tional level or lack of knowledge of the Spanish lan-
guage; or were under pharmacological treatment likely
to interfere with their ability to understand and answer
the questions on the scale. Once a case was identified
and enrolled in the study, a control subject was selected
concurrently at the participating centre from among
those subjects attending the clinic for any reason unre-
lated to an anxiety disorder. Thus controls were age-
(± 5 years) and sex-matched subjects without a diagnosis
of anxiety disorder of any kind and no symptoms of anx-
iety (HAM-A< 10). Sample size was estimated with re-
spect to sensitivity of the GAD-7 scale for screening
possible cases of the target disease (GAD). We needed
100 participants with GAD to ensure that the total width
of the 95% confidence interval around a sensitivity pro-
portion of 0.90 was no greater than 0.05, given that the
estimated prevalence of GAD in clinic populations in
Spain ranges between 6% and 8% (ESEMeD/MHEDEA)
[2,7]. A similar sized age- (± 5 years) and sex-matched
control group (without GAD) was also enrolled. We
increased the sample size by 5% to allow for losses of in-
formation in the statistical analysis. Patients were ran-
domly selected as they attended consultation by 14
investigators (family doctors in urban zones in the pro-
vinces of Madrid, Zaragoza and Barcelona). In the end,
the sample comprised a total of 212 individuals, half in
the GAD group and the other half in the control group.
The GAD-2 vs GAD-7 concordance sample was
recruited following the same inclusion/exclusion criteria
used in the cultural adaptation sample. A sample of 60
patients was assumed to be sufficient to estimate the
correlation between scales.
Concurrent instruments
The 7-item generalised anxiety disorder scale (GAD-7)
is a self-administered instrument whose overall score is
computed by addition of the item scores (see Table 1).
Each of the 7 component items can be assigned one of
the following values: 0 (never), 1 (several days), 2 (more
than half of the days) or 3 (almost every day). Theoret-
ical overall score can range between 1 and 21 points and
may be used to assign patients to one of the following
severity levels: minimal (0 – 4), mild (5 – 9), moderate
(10 – 14) or severe (15–21). The questionnaire has ex-
cellent reliability and discriminant properties: Cron-
bach’s α= 0.92; area under the curve (AUC) = 0.91. Using
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a cut-off score of ≥10, a sensitivity = 0.86 and specifi-
city = 0.82 have been obtained in primary care patients
[3]. General population norms have been published [31].
The 2-item generalised anxiety disorder scale (GAD-2)
is composed of the first two items of the GAD-7 and
they gather information on the two core GAD symptoms
(see Table 1). The overall score is obtained by simple
addition of item scores. Each individual item can be
scored between 0 (never) and 3 (almost every day). The
overall score can range between 0 and 6 and can be used
to assign patients to the following severity levels: min-
imal (0–2) and severe (3–6). Using a cut-off value ≥3, a
sensitivity = 0.86, specificity = 0.83, positive predictive
value (PPV) = 0.34 and negative predictive value (NPV) =
0.94 were obtained when Web-based administration
methods were used, along with an AUC=0.91 [3]. Using a
cut-off value ≥4, the Web-administration discrimination
values obtained were: sensitivity = 0.83, specificity = 0.61,
PPV=0.34, NPV=0.94 and AUC=0.76 [25].
The Hamilton Anxiety Scale (HAM) [16] is a 14-item,
hetero-administered scale formulated as a semi-
structured interview to assess the subject’s level of anx-
iety. Items are scored from 0 (absent) to 3 (severe). The
total score ranges from 0 to 42 points and may be cate-
gorized into four severity groups: normal (0 – 9), mild
(10 – 15), moderate (16 – 24) and severe (25 – 42).
The Hospital Anxiety and Depression Scale (HADS)
[17] is a 14-item, self-administered scale with Anxiety
and Depression being assessed by 7 items each. Each
item is scored from 0 to 3 with several anchors. Some
items are assessed positively and others negatively. A
score between 0 and 21 points may be obtained in each
domain. The score in each domain may be categorized
into four severity groups: normal (0 – 7), mild (8 – 10),
moderate (15 – 21) and severe (15 – 21).
The World Health’s Organization Disability Assess-
ment Scale (WHO-DAS II 12 items version) [30] is a 12-
item, self-administered scale. Items are grouped by pairs
in 6 domains: 1- Understanding and communicating
with the world, 2- Moving and getting around, 3-Self
care, 4-Getting along with people, 5-Daily life activities
(domestic responsibilities, leisure, and work), and 6-
Participation in society. This scale contains another 5
items, one about overall health and four about the num-
ber of days with activity limitations in daily life. Scoring
is standardized on a 0–100 metric, where 0 means no
disability and 100 the highest disability.
Statistical analysis
Firstly item analysis was performed by computing the
selection frequency for each response category, along
with non-responses. Reliability was assessed by comput-
ing internal consistency using Cronbach’s alpha [32]
and the correlation between the GAD-2 items and
those same items extracted as a subscale from the
GAD-7. The intra-class correlation coefficient (ICC) for
individual measures was computed to prevent question-
naire length from affecting the estimates. GAD-2 scor-
ing discriminative capability was assessed by dividing
the study sample into four quartile groups based on the
GAD-7 total score and comparing the first and fourth
quartile group mean scores on the overall score and
also on the individual item scores. These comparisons
could be considered an estimate of GAD-2 discriminant
validity.
An adapted version of the multiple indicator multiple
cause (MIMIC) model was estimated using structural
equation modelling [33] in order to determine whether
there might be an effect of presentation order (GAD-2
first vs. GAD-7 first) on the mean GAD-2 value when
comparing the estimated mean true score for the GAD-2
(T-GAD2) and the mean true score obtained using the
extracted GAD-7 subscale (T-GAD7). The model esti-
mates the effect (γij) of presentation order (0=GAD-2
first, 1 =GAD-7 first) in terms of deviation from the
mean reference value. If no significant effects were
found we would be able to conclude that there is no
order effect. The model also estimates the measurement
capabilities of the individual items (λ loadings) for
gauging the true score, whether presented in the GAD-2
alone or the extracted GAD-7 subscale. Measurement
loadings should be similar. Raw estimates are reported
in order to represent item mean values and error vari-
ance estimates and because of the known bias
Table 1 GAD-7 and GAD-2 items
Spanish English Scale
Sensación de nerviosismo, de ansiedad, de tener los nervios de punta Feeling nervous, anxious, or on edge GAD-7, GAD-2
Incapacidad para eludir o controlar la preocupación Not being able to stop or control worrying GAD-7, GAD-2
Preocupación excesiva por cosas diferentes Worrying too much about different things GAD-7
Dificultad para relajarse Trouble relaxing GAD-7
Una intranquilidad de tal grado que no puede estarse quieto Being so restless that it is hard to sit still GAD-7
Facilidad para enfadarse o irritabilidad Becoming easily annoyed or irritable GAD-7
Sensación de miedo, como si pudiera ocurrir algo terrible Feeling afraid as if something awful might happen GAD-7
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introduced by the regular standardisation method [34].
The discriminant capabilities of the GAD-2 were
assessed using the receiver operating characteristic
(ROC) curve statistics, against the clinician diagnosis
using DSM-IV criteria. AUC was estimated, along with
sensitivity, specificity, PPV and NPV for each possible
cut-off point value. The ROC curve was compared with
those for the GAD-7, HADS, HAM-A and WHODAS II
scales. AUC for the GAD-2 was statistically compared
against GAD-7 using the method proposed by Hanley
and McNeil [35]. Correlations of GAD-2 with other
measures were computed, i.e. GAD-7, HADS-Anxiety,
HADS-Depression, HAM-A, WHODAS II overall score,
WHO-DAS II Dimensions and number of visits to the
clinician in the last month.
All computations were done using IBM SPSS Statistics
for Windows v19.0 and AMOS 18.0 software [36,37].
Results
Table 2 summarises the main characteristics of the cul-
tural adaptation and the concurrent measurement sam-
ples. The latter comprised 62% women with an average
age of 37 years (SD= 10.7, min = 20, max = 58). GAD
time since diagnosis varied between 11 months and
23 years with an average of 6.9 years (SD= 5.6).
Feasibility
None of the GAD-2 items were left blank. Hence, no
item comprehension problems were found and issues on
pertinence were also not found during the validation
process. In the concurrent measurement sample only
one individual left one of the GAD-7 items blank, i.e.
item 4 (Trouble relaxing). In general responses were
spread over all the response categories and the existence
of a floor or ceiling effect was discarded. In all items the
most frequent response category was the middle one.
The percentage of responses in the higher categories
varied between 18% and 32% and the percentage of
responses in the lower categories varied between 0 and
3%. The distribution of responses on the GAD-2 was
similar with 20-25% of responses in the highest category
and 2-5% in the lowest category. All items were distribu-
ted with a roughly symmetric shape and a skewness
index between 0.393 and 0.295 (SE = 0.311).
Reliability
In the version concordance sample, Cronbach’s alpha for
the GAD-2 was 0.927, which is close to the value of 0.936
obtained in the cultural adaptation sample. The ICC for
individual measures was 0.707 with an associated 95%
confidence interval of (0.554-0.814), while for the GAD-7
it was 0.644 and (0.547-0.739). Regarding the stability of
instrument, the mean time between administrations of the
GAD-2 and the GAD-7 was 5.9 days (SD=2.11). When
the GAD-2 was administered first, the correlation between
GAD-2 items and the extracted GAD-7 subscale was high
and significant (r = 0.898, p < 0.001). The estimated reli-
ability for the GAD-2 was α=0.879 and for the extracted
GAD-7 subscale was α=0.826. The mean value for the
GAD-2 (mean=3.80, SD= 1.58) was slightly lower than
for the extracted GAD-7 subscale (mean=3.97, SD= 1.47),
but differences were not significant (dif =−0.17, p = 0.202).
When the GAD-2 was presented second, the correlation
between formats was again high and significant (r = 0.837,
p < 0.001), while the reliability for the GAD-2 was slightly
higher (α=0.780) than for the extracted GAD-7 subscale
(α=0.695). Again the slight difference between GAD-2
mean=3.73 (SD=1.36) and extracted GAD-7 subscale
mean=3.97 (SD=1.35) was not significant (dif =−0.23,
p = 0.109).
Comparing the presentation format subsamples, no
significant differences were found in the GAD-2 mean
score (dif = 0, SE = 0.365, p = 1.00) nor in the extracted
GAD-7 subscale (dif =−0.07, SE = 0.382, p = 0.86) nor in
the GAD-7 overall score (dif = 0.23, SE = 1.16, p = 0.85).
In the cultural adaptation sample, the test-retest cor-
relation between GAD-2 scores (extracted from the
GAD-7) was 0.744.
Presentation order effect
Figure 1 represents raw estimates of the structural equa-
tion model estimating the effect of the presentation for-
mat (GAD-2 first vs GAD-7 first). The model attained a
good fit with a non-significant value for χ2 = 5.48 (df = 3,
p = 0.140) indicating that the model is able to properly
reproduce the observed means, variances and covar-
iances for the 4 items. Most goodness-of- fit-statistics
were adequate: χ2/df = 1.83, CFI = 0.984, NFI = 0.966,
while the RMSEA= 0.118 was slightly poor. All esti-
mated weights were significant (p < 0.001). Weights asso-
ciated with the presentation order effect (γ11 =−0.01 and
γ21 =−0.06) on the true mean scores (T-GAD7 and T-
GAD2) were not significant (p = 0.936 and p = 0.742, re-
spectively), which allows us to conclude that there is no
presentation order effect.
Discriminant validity
Comparing quartile 1 and 4 groups created based on
GAD-7 scores, both GAD-2 items showed significant
differences (p < 0.001) as did the overall score (see
Figure 2). Variances could be assumed to be similar in
both groups, although item 1 was clearly homoscedastic
(p = 0.843) while item 2 was close to rejection of the
equal variances hypothesis (p = 0.075). We can conclude
that both items are able to discriminate between low
and high scores and both items contribute in the over-
all score to discrimination. In the concurrent measure-
ment sample, the GAD-2 overall score was able to
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detect significant differences between GAD screened
individuals (GAD-7 ≥ 10: mean = 4.28, SD= 1.14) and
non-GAD individuals (mean = 1.92, SD= 0.95). Differ-
ences between mean scores were significant (p < 0.001)
while variances were similar (p = 0.122; see Figure 2). In
the cultural adaptation sample, the value for the area
under the ROC curve for the GAD-2 was AUC= 0.918
(SE = 0.037) allowing us to reject the null hypothesis of
0.5 (which would have indicated that it was not possible
to discriminate between GAD and control individuals).
The 95% confidence interval was (0.846-0.991) indicat-
ing excellent discrimination between groups. Using a
cut-off value of 3, a sensitivity of 84.6%, a specificity of
87.5%, PPV= 97.8% and NPV= 46.7% were achieved
(see Table 3).
Screening
Figure 3 represents ROC curves for the behaviour of
different diagnostic scales with respect to clinician diag-
nosis. AUC for the GAD-2 was 0.937 (95% CI: 0.902 –
0.971) which includes the central value obtained for the
GAD-7 (0.957, SE = 0.015), HAM-A (0.969, SE = 0.013)
and HADS-A (0.946, SE = 0.016) but not for the WHO-
DAS II (0.868, SE = 0.024) nor HADS-D (0.867,
Table 2 Summary and comparison of socio-demographic and clinical variables by study group
GAD Group (n = 110) Control Group (n= 110) p Reliability (n = 60)
Age (years): mean (SD) 47.1 (15.6) 48.0 (16.1) 0.679 37.2 (10.7)
Gender (% women) 72.6 72.6 1.000 62.1
BMI (kg/m2) 26.1 (4.8) 25.8 (4.2) 0.635 24.9 (3.4)
Race (% white) 98.1 100 0.498 100
Education (%) 0.262
None 5.7 1.9 0
Primary 35.8 30.2 21.7
Secondary 24.5 29.2 38.3
Professional Degree 17.0 13.2 13.3
Higher 17.0 25.5 26.7
Marital Status (%) 0.596
Single 18.9 15.2 28.3
Married 67.0 65.7 43.3
Separated/Divorced 6.6 8.6 26.7
Widowed 7.5 8.6 1.7
Other 0 1.9 0
Labour Status (%) 0.095
Home-maker 17.9 22.9 10.0
Active 58.5 62.9 45.0
Unemployed 2.8 4.8 33.3
Disabled 10.4 1.9 8.3
Retired 10.4 7.6 3.3
People in Treatment (%) 79 20 < 0.001 NR
Number of Treatments 1.30 (0.11) 0.06 (0.03) < 0.001 NR
Disorder history (years) 3.49 (0.40) NA NA 6.87 (5.56)
HAM 26.54 (9.11) 6.74 (5.12) < 0.001 NR
HADS-A 12.59 (4.41) 4.08 (2.40) < 0.001 NR
HADS-D 8.84 (4.99) 2.51 (2.85) < 0.001 NR
GAD-7 13.96 (4.19) 3.54 (3.32) < 0.001 13.15 (4.46)
GAD-2 4.58 (1.31) 1.21 (1.39) < 0.001 3.77 (1.47)
WHODAS-II (overall) 35.78 (22.3) 8.94 (11.8) < 0.001 NR
NA=Not applicable, NR=Not recorded, HAM-A=Hamilton Anxiety scale, HADS=Hospital Anxiety Depression Scale, GAD-7= 7-item Generalised Anxiety Disorder
scale, GAD-2= 2-item Generalised Anxiety Disorders scale, WHODAS II=World Health Organisation Disability Assessment Scale II. Data expressed as mean (standard
deviation) or percentage.
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SE = 0.025). GAD-2 AUC was not significantly different
from the one obtained using the GAD-7 (χ2 = 3.34, df =
1, p = 0.0675). The best discrimination cut-off value for
the GAD-2 was ≥3 with the following discrimination in-
dexes: sensitivity = 91.5%, specificity = 85.8%, PPV=
86.6% and NPV= 91.0%. GAD-2 correlation with other
scales was high and significant in all cases (p < 0.001):
GAD-7 (0.940), HAM-A (0.806) and HADS-A (0.825),
except with WHODAS II (0.642) which was compara-
tively lower (see Tables 4 and 5).
Discussion
The results obtained support the hypothesis that the
GAD-2 is a reliable and valid measure for the screening
of GAD, both when it is administered alone and when it
is extracted as a subscale from previous GAD-7 adminis-
trations. Despite the brevity of the scale, good internal
consistency ensures that GAD core symptoms are well
assessed by the GAD-2. High test-retest correlation
reveals good stability over time, suggesting that we are
measuring a steady trait in patients as long as no
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Figure 1 Structural equation model estimating the impact of presentation order format (GAD-2 first = 1, GAD-7 first = 0) on true GAD
mean scores. T-GAD7= True GAD-2 subscale score extracted from the GAD-7 scale, T-GAD2= True GAD-2 score. GAD7_1 & GAD7_2: observed
GAD-7 items. GAD2_1 & GAD2_2: observed GAD-2 items.
Figure 2 GAD-2 mean and 95% confidence interval (CI) by percentile group (left) and by GAD-7 screening (right). Concurrent
measurement sample.
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treatment is initiated. The scale is well understood, easy
to answer and faster to complete than other question-
naires, demonstrating its high feasibility. GAD-2 scores
are able to discriminate between individuals with high
and low GAD symptom scores as shown by quartile
group comparison. Construct validity is evidenced by
the ability to differentiate between patients and controls
when detection is done by the clinician and also when
other diagnostic scales are used. Predictive validity is
confirmed by the good value obtained for the area under
the curve, which is even better than values obtained in
other samples [25]. Furthermore the GAD-2 screening
feature is similar to the extended GAD-7. Convergent
validity was proven by the high correlation with other
diagnostic scales: GAD-7, HAM-A and HADS, while di-
vergent validity was revealed by the relatively lower cor-
relation with the WHODAS II.
The estimated structural equation model confirmed
that the GAD-2 true mean score remained stable regard-
less of presentation order (before or after the GAD-7),
and the GAD-2 score was not favoured by prior admin-
istration of the GAD-7. Furthermore GAD-2 values may
be extracted from previous studies where the GAD-7
was used without loss of accuracy. Goodness-of-fit sta-
tistics were excellent even though this was not the cen-
tral issue in the model, which only intended to obtain
estimates of the presentation order effect. Although it is
not reported here, a similar confirmatory model was
estimated to assess the stability of the GAD-2 true score
regardless of whether it was measured alone or in con-
junction with the rest of the GAD-7 items, supporting
the hypothesis that the items are stable in both situa-
tions (tau equivalent measures). Some authors have pro-
posed further reducing the GAD-7 and leaving it
condensed into one single item [25], as it has been
shown with other instruments, just to facilitate its use at
primary care levels [38]. However, this is a controversial
matter. In our opinion, that is consistent with previous
research also considering that one item may not be as
good as longer screeners [38-41], this strategy is not ap-
propriate. Firstly because, from a psychometric perspec-
tive, measurement by a single item does not distinguish
the variance attributed to measurement error from true
score variability. Secondly the proposal by these authors
is based on selecting the item with the highest predictive
properties by testing regression models containing all
GAD-7 items. This analytical strategy does not ensure
the psychometric properties of the individual item
selected nor does it take into account the context effect
of answering the other items present in the scale, a topic
we have been able to explore. And finally, because the
differential burden of administration of a scale with two
or one item seems negligible.
Given the good screening properties of the GAD-2, we
recommend its use as a screening tool for early detec-
tion of this disorder. However it seems reasonable to
prefer the GAD-7 to assess the effect of pharmacological
or psychotherapeutic treatments and the follow-up of
patients, since it has broader psychometric properties
and more sensitivity. It should be taken into account
that typical screening processes will question the pres-
ence of more than one psychological and physical prob-
lem, and could convey administering more than one
specific questionnaire (eg.: Minimental for dementia,
HADS for depression, etc.) and a whole battery of tests
Table 3 GAD-2 discriminant values for different cut-off
points
Cut-off Sensitivity Specificity PPV NPV Cases
0 100 0 50 50 212
1 99.1 39.6 62.1 97.7 169
2 97.2 67.0 74.6 95.9 138
3 91.5 85.8 86.6 91.0 112
4 84.9 92.5 91.8 86.0 98
5 56.6 96.2 93.8 68.9 64
6 29.2 98.1 93.9 58.1 33
Note: PPV= Positive Predictive Value, NPV=Negative Predictive Value. Values
are%.
Figure 3 ROC curve for the GAD-2 and concurrent scales.
Table 4 GAD-2 correlations with other concurrent scales
GAD-2 GAD-7 HADS-Anxiety HADS-Depression
GAD-7 0.940**
HADS-Anxiety 0.825** 0.903**
HADS-Depression 0.650** 0.706** 0.724**
HAM 0.806** 0.852** 0.833** 0.756**
**Correlation is significant at the 0.01 level (2-tailed).
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could be desirable. In such situations brief screening
instruments should show to be valuable tools. It is im-
portant to remember that this instrument is available to
all professionals and it can also be accessed on-line on
Web health portals, which may be helpful given the high
prevalence and comorbidity of this disorder. Neverthe-
less it should be noted that the screening cut-off points
for Web-based administration (both for the GAD-2 and
the GAD-7) have been slightly higher than the paper
and pencil version [25], although we have not assessed
Web-based properties in our own study.
One shortcoming of the present study is that measure-
ments have been carried out in a primary care environ-
ment and other authors have shown that GAD-7 scores
are slightly higher in this context compared with a gen-
eral population context (means of 5.57 and 2.95, respect-
ively) [31]. Another limitation of our study is that we did
not study the comorbidity influence of other psycho-
logical disorders that might be present such as other
anxiety disorders or major depressive disorders. We have
seen that that a moderate correlation between GAD and
Depression scores exists (see Table 4) accounting for
42% of common variance. This limitation has been
found before and some authors suggest incorporating an
additional question assessing depressed mood, which
could be added when a person scores positive on the
GAD-7 to distinguish between GAD and Depressive Dis-
order [25]. Even more when depression diagnostic tools
like HAM-D have shown to be able to have detection
capabilities for GAD (AUC=0.867) although they be-
have significantly worse than GAD specific instruments
(p = 0.0062). Given the high level of co morbidity within
mental health disorders, a stepwise screening procedure
is recommended in order to screen for psychiatric disor-
ders when using self-reported instruments. A short
questionnaire screening for the suspected disorder could
be used as a first step. If subjects score positive on the
specific subscale, they can then undergo more in-depth
screening with the appropriate longer questionnaire or
diagnostic interview. This type of screening is being
investigated [42].
Conclusion
In summary, despite the identified limitations, the Span-
ish for Spain version of the GAD-2 scale has been shown
to have appropriate psychometric properties for rapidly
detecting probable cases of GAD in the Spanish cultural
context under conditions of routine clinical practice.
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